All articles by GlobalData Healthcare

Outsourcing gap widens: Europe pulls away from US in new drug manufacturing

In 2025, the dose outsourcing gap between the proportion of newly approved biosimilar and innovator products outsourced to European and…
EAN 2026: Bocunebart’s promise as migraine preventive in treatment-refractory patients

On 29 June, at the 12th Congress of the European Academy of Neurology (EAN) 2026, as part of a late-breaking…
Surge in RMAT designations awarded by the FDA

Since the first time the US Food and Drug Administration (FDA) awarded a regenerative medicine advanced therapeutic (RMAT) designation in…
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s

AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…
EAN 2026: following EU approval, AbbVie highlights Aquipta efficacy for acute migraine

On June 27, at the 12th Congress of the European Academy of Neurology (EAN) 2026, three e-posters with results from…

EAN 2026: New Fintepla data in Dravet Syndrome and LGS

Researchers at the Brno Epilepsy Centre in Czechia announced data from a retrospective, single-centre observational study evaluating the efficacy and…
ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1

On 6 June, at the 86th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, findings from…
EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline candidates in multiple myeloma (MM) at the European Hematology…
EHA26: J&J’s multiple myeloma therapies impress with new data

Johnson & Johnson (J&J) has shared data from several studies evaluating two of its approved therapies in multiple myeloma (MM)…
EHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML

At the European Hematology Association (EHA) 2026 Congress, updated results from the Phase Ia RevSTAR-123 trial were presented on June…